How many days should budesonide oral suspension (Eohilia) be used for?

Budesonide oral suspension (Eohilia) is a short-course, topical corticosteroid designed to treat patients with eosinophilic esophagitis (EoE). Unlike inhaled or oral tablet budesonide, Eohilia's drug is designed to relieve inflammation in the short term and promote esophageal mucosal repair, so the course of treatment has a clear time limit.

According to the U.S.FDA instructions, the recommended course of treatment for Eohilia is 2 mg orally daily for 12 weeks. This is the longest course of treatment currently approved, and continued use beyond this time lacks data support for safety and effectiveness. The setting of the 12-week treatment course is mainly based on the pharmacokinetic characteristics of the drug and the research results of the disease remission cycle. Most patients experience significant improvement in inflammation and relief of swallowing symptoms during this cycle.

Overseas guidelines state that long-term or repeated courses of budesonide suspension should be used with caution. Since it is a glucocorticoid drug, long-term continuous use may increase the risk of side effects caused by systemic absorption, such as adrenal suppression, decreased immune function, oral or esophageal candida infection, etc. Therefore, doctors usually reassess the condition after the course of treatment and then decide whether to carry out maintenance treatment or discontinue medication for observation.

In addition,Eohilia’s treatment course should be individually adjusted under the guidance of a doctor. For patients with severe illness or frequent relapses, doctors may adopt an intermittent treatment model, that is, short-term use during the symptom exacerbation period, and then entering the observation period to balance efficacy and safety. Patients should not extend the course of treatment or change the dosage without authorization, otherwise it may destroy the local balance of the drug and increase side effects.

After the drug is discontinued, if symptoms recur or dysphagia worsens, a follow-up visit should be made in a timely manner. Some patients may need to re-evaluate the extent of their esophagitis and combine it with other treatments, such as antacid medications or dietary management, to maintain long-term remission.

Reference materials:https://www.drugs.com